Leflunomide
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Leflunomide: From Rheumatoid Arthritis to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Leflunomide is a DHODH (dihydroorotate dehydrogenase) inhibitor pharmacologically associated with rheumatoid arthritis and other autoimmune conditions. The TxGNN model predicts a possible link to Brachydactyly-Syndactyly Syndrome, but this prediction is currently supported by no clinical trials and no published literature — it rests entirely on a knowledge-graph inference score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (pharmacological rationale references autoimmune disease, e.g. rheumatoid arthritis) |
| Predicted New Indication | Brachydactyly-Syndactyly Syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, verified mechanism of action data was not available in this evidence pack (flagged as a High-severity data gap). Based on the pharmacological rationale accompanying the prediction, leflunomide is understood to act as a DHODH inhibitor, blocking the de novo pyrimidine synthesis pathway and producing anti-proliferative and immunomodulatory effects — a mechanism associated with treatment of autoimmune conditions such as rheumatoid arthritis.
Brachydactyly-syndactyly syndrome is a congenital skeletal malformation syndrome, with pathology typically driven by disrupted embryonic limb-patterning genes (e.g. HOX and BMP signalling pathways) rather than by inflammatory or immune-mediated processes. There is no established mechanistic bridge between DHODH-mediated pyrimidine synthesis inhibition and the developmental gene pathways implicated in this syndrome.
Consequently, the biological plausibility of this prediction is low. The link identified by TxGNN appears to be a statistical association within the knowledge graph rather than one supported by known pharmacology, and should be interpreted with substantial caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No marketing authorisation records are present in this evidence pack. Leflunomide is currently recorded as Not Marketed within the scope of this dataset, with zero associated licences.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5 evidence), with no clinical trials, no published literature, and a mechanistically implausible link between an immunomodulatory DHODH inhibitor and a congenital skeletal malformation syndrome. This does not meet the threshold to proceed to safety or clinical evaluation.
To proceed, the following is needed:
- Verified mechanism of action (MOA) data for leflunomide (currently a High-severity data gap)
- UK/MHRA product labelling, warnings, and contraindications (currently a Blocking-severity data gap)
- Independent literature or preclinical evidence establishing a biological rationale linking DHODH inhibition to skeletal developmental pathways
- Re-evaluation once any clinical, case-report, or mechanistic evidence becomes available for this specific indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.